TMO - Thermo Fisher Scientific Inc
The world leader in scientific instrumentation and life science services, supplying laboratories and pharmaceutical manufacturers with the tools to accelerate research.
Finlify Score
44.0 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$473.72
+0.93%
52W Range
$385.46 - $643.99
Market Cap
$183.0B
+0.9%Compared to previous day
2026 Q1 Revenue
$11.0B
-9.9%Changes from last reporting quarter
2026 Q1 EPS
$4.43
Diluted shares
Analyst Rating
34 analysts in latest ratings feed
RSI
59.1
40-70 moderate
2Y Range Position
34%
-26.4% from high / +22.9% from low
Beta
0.88
Relative to market benchmark
MACD
0.72
MACD line 1.69 / signal line 0.96
Fundamental Trend
Growth 30.1Financial Health
Quality 57.9Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID44.0 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $11.0B-9.9% | $12.2B+9.8% | $11.1B+2.5% | $10.9B+4.7% |
| Gross Profit | - | - | - | - |
| Operating Income | $1.9B-17.4% | $2.3B+16.2% | $1.9B+5.7% | $1.8B+6.9% |
| Net Income | $1.7B-15.9% | $2.0B+21.5% | $1.6B+0.2% | $1.6B+6.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
Finlify's quantitative signal for TMO on 2026-06-12 is AVOID, with an overall Finlify Score of 43.7/100, which suggests a cautious stance based on its component scores.
Technical
The asset's Relative Strength score of 27.8/100 appears relatively low, indicating potential underperformance compared to its peers, and it is trading 26.6% below its 52-week high. However, a strong Accumulation / Volume score of 79.1/100 could suggest some underlying buying interest, despite a modest 60-day return of 1.0%. The RSI(14) of 48.2 indicates a neutral momentum posture.
Fundamentals
The Fundamental Trend score of 30.1/100 appears low, which might signal some concerns regarding its business momentum, even as Financial Quality registers a moderate 57.9/100. Valuation metrics such as a P/E of 26.1x, P/B of 4.1x, and P/S of 3.9x may suggest the asset is trading at somewhat elevated levels. TMO also offers a modest dividend yield of 0.40%.
Macro Context
The current macro environment, characterized by a CPI YoY of 4.3% and a 10Y Treasury Yield of 4.5%, may present a challenging backdrop for growth-oriented assets like TMO. Higher interest rates could potentially impact the cost of capital for TMO and its customers in the life sciences sector.
Key Risks
- The asset's low Relative Strength score of 27.8/100 and significant distance from its 52-week high (-26.6%) may indicate persistent underperformance.
- A low Fundamental Trend score of 30.1/100 suggests potential concerns regarding the company's underlying business momentum.
- Valuation multiples, including a P/E of 26.1x, appear somewhat elevated, which could be a consideration in the current higher interest rate environment.